KDR and breast carcinoma: Other notable large performances are the ones of two classifiers on pancreatic cell lines: ZD-6474 (vandetanib [43], a VEGFR/EGFR inhibitor) scoring BA = 0.83 for 5 sensitive and 9 resistant cell lines and sorafenib [44], a large-spectrum kinase inhibitor (BA = 0.96 for 6 sensitive and 9 resistant cell lines), the RAF/VEGFR2 inhibitor RAF265 [45] for ovarian cancer (BA = 0.85 for 9 sensitive and 2 resistant cell lines), and the EGFR inhibitor Erlotinib [46] for breast cancer (BA = 0.85 for 5 sensitive and 10 negative cell lines).